Filing Flows › Gilead Sciences (GILD) › Capital expenditures
Gilead Sciences (GILD) capital expenditures by quarter
Gilead Sciences' capital expenditures were $237M in Q3 2026 (third quarter 2026), +69% from Q2 2026. Over the last 7 quarters it ranged from $104M (Q1 2025) to $237M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $237M | +69% | +61% |
| Q2 2026 | $140M | +20% | +31% |
| Q1 2026 | $117M | -43% | +12% |
| Q4 2025 | $205M | +39% | — |
| Q3 2025 | $147M | +37% | — |
| Q2 2025 | $107M | +3% | — |
| Q1 2025 | $104M | — | — |
Q3 2026 at a glance
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Gilead Sciences' capital expenditures?
Gilead Sciences' capital expenditures were $237M in Q3 2026 (third quarter 2026), +69% from Q2 2026.
How has Gilead Sciences' capital expenditures changed?
Over the last 7 quarters it ranged from $104M (Q1 2025) to $237M (Q3 2026).